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The potential utility of abbreviated breast MRI (FAST MRI) 1 
as a tool for breast cancer screening: a systematic review 2 
and meta-analysis 3 




A systematic review and meta-analysis was conducted to synthesise published evidence 8 
comparing abbreviated protocol (AP) MRI to full protocol breast MRI (FP) to detect breast 9 
cancer in a screening setting. The review focuses on the first post contrast subtracted (FAST) 10 
protocol and compares indices of diagnostic accuracy and scan acquisition and reporting 11 
times. A systematic search for articles in Medline, Embase and Cochrane databases was 12 
undertaken. Cohort studies without enrichment were included if they presented data on 13 
accuracy of AP MRI in a screening setting for any level of risk (population, moderate and 14 
high risk). Level of evidence was assessed using the Grading of Recommendations 15 
Assessment, Development and Evaluation (GRADE) approach. A meta-analysis for AP MRI, 16 
with FP and histology from FP positive cases as reference standard was conducted using a 17 
bivariate random effects model. An additional meta-analysis was performed with follow up to 18 
symptomatic detection added to the FP reference standard. In addition, the review covers 19 
published evidence comparing AP MRI with mammographic modalities (digital 20 
mammography, tomosynthesis and contrast enhanced spectral mammography).  21 
Our search retrieved 23 articles, of which five studies (6 articles) were included, with a total 22 
of 2,763 women (3,251 screening rounds). The GRADE assessment rated the overall level of 23 
evidence as very low, in particular because the reference standard was interpreted with 24 
knowledge of the index test and because biopsy was not obtained for AP positives.  The 25 
overall sensitivity for AP MRI, with FP (and histology for FP positives) as reference 26 
standard, was estimated as 94.8% (95% CI 85.5-98.2) and the specificity as 94.6% (95% CI 27 
91.5-96.6), which gave an area under the receiver operator curve of 97.5. Three published 28 
studies, including 1,450 women (1,613 screening rounds), presented follow up data that 29 
allowed a comparison between AP and FP MRI. The sensitivities for AP did not significantly 30 
differ from those for FP (p=0.83) nor did the specificities (p=0.37). 31 
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There is a very low level of evidence that suggests AP MRI could be an accurate test for 32 
breast cancer screening. High quality research is required with follow up to interval cancer to 33 
determine the effect its use could have on clinical outcome.  34 






 Abbreviated breast MRI (abMRI) detects cancer in mammography negative cases 41 
 Sensitivity and specificity of abMRI compared to full protocol MRI were both 95% 42 
 Accuracy of abMRI and fpMRI may be similar but evidence quality is very low 43 




Magnetic resonance imaging (MRI) is the most sensitive imaging modality for the detection 46 
of breast cancer1,2, and can find small cancers of 5mm and smaller3–5. As a screening tool for 47 
breast cancer in the very high risk population (>30% lifetime risk) it increases both early 48 
cancer detection and metastases-free survival6 and is the standard of care for these women in 49 
the UK and internationally. Nevertheless, breast MRI is a high cost investigation, secondary 50 
to its long scan acquisition time and the time taken for image interpretation. This limits its 51 
cost effectiveness for use as a screening tool in other populations of women with lower breast 52 
cancer prevalence, despite evidence that it could provide for them increased early cancer 53 
detection and reduced interval cancer rate7,8. In addition, the length of time spent inside the 54 
MRI scanner during a breast MRI examination has been shown to be a significant source of 55 
discomfort in over a third of women undergoing the investigation9,10 and so a reduction in the 56 
scan time would potentially improve the screening clients’ experience. 57 
In 2014 Kuhl et al. introduced the concept of an abbreviated protocol for breast MRI 58 
(abMRI):  First post contrast Acquisition SubTracted (FAST) protocol11. This proof of 59 
concept study investigated whether a single pre and post contrast acquisition with derived 60 
images (FAST) and maximum-intensity projection (MIP) was suitable as an alternative to the 61 
full protocol (fpMRI) for screening. Their published results were promising with the MRI 62 
acquisition time reduced to just 3 minutes and an image interpretation time of <30 seconds 63 
whilst diagnostic accuracy was maintained, equivalent to the fpMRI. As a consequence of 64 
Kuhl’s original research, several authors have published articles exploring the utilisation of 65 
an abMRI for detecting breast cancer12–20, including several variations of the original FAST 66 
format in an attempt to increase the specificity. These variations include the addition of T2 67 
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sequences and diffusion weighted imaging and a number of reviews have been written about 68 
the technique21–24. 69 
Parallel to Kuhl’s development of the FAST protocol abMRI for use in breast screening, 70 
Mann et al. suggested that an “ultrafast” abMRI protocol, originally described by Hermann et 71 
al. in 201125, utilising a time resolved magnetic resonance angiography technique (Time-72 
resolved angiography With Stochastic Trajectories (TWIST)) that provided additional kinetic 73 
information, could be used for the same indication26. They concluded that calculating the 74 
maximum slope of the relative enhancement-versus-time curve obtained from the TWIST 75 
sequences allowed discrimination of benign and malignant breast lesions with high accuracy. 76 
This early study on Ultrafast MRI has been supported by subsequent studies that confirm that 77 
a steep slope and a short time to enhancement both correlate with malignancy27–31. 78 
With the advent of personalised screening, women are likely to be stratified according to their 79 
level of risk to different screening regimes/imaging modalities with the potential to increase 80 
the number of women offered a screening modality more sensitive than mammography32. 81 
Published studies of abMRI techniques have used expert MRI readers for interpretation, and 82 
this has been suggested as a potential barrier to expansion of the technique for personalised 83 
screening with abMRI24. However, with a single day’s standardised training33 to interpret the 84 
simplest of the abMRI techniques (FAST MRI), an early study suggests that professionals 85 
who are already competent at reading mammograms can achieve similar levels of accuracy of 86 
interpretation of abMRI to that of expert breast MRI readers34. If these results should be 87 
validated in subsequent studies35, limitation to expansion of the role of abMRI (FAST 88 
protocol) on the grounds of workforce feasibility will have been reduced. 89 
Although individual studies of abMRI have suggested it might offer a diagnostic accuracy 90 
similar to fpMRI with acquisition and reporting times nearer to those of mammography, there 91 
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has been little direct comparison of abMRI with mammography reported in the literature. In 92 
order to decide whether abMRI could replace fpMRI for high risk population screening, we 93 
need to understand how it compares in diagnostic accuracy. There is also a potential role for 94 
abMRI to replace mammograms for moderate risk screening although for this to be cost 95 
effective its diagnostic accuracy would need to be demonstrably sufficiently greater than that 96 
of mammograms to justify its higher cost. 97 
The primary objective of this systematic review was to assimilate published evidence to 98 
compare the diagnostic accuracy of breast cancer detection of abMRI (that includes the FAST 99 
protocol) with that of fpMRI in the screening setting. 100 
The secondary objectives were: 101 
- To compare the abMRI and fpMRI scanning acquisition and reporting times  102 
- To compare the diagnostic accuracy of abMRI with that of any mammographic modality 103 
(standard digital mammography, digital breast tomosynthesis and contrast enhanced spectral 104 
mammography). 105 
-  106 
Materials and methods 107 
The systematic review and meta-analysis were conducted in accordance with the Preferred 108 
Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidance36. 109 
Search strategy 110 
A systematic literature search for relevant articles was performed in November 2019. The 111 
keywords utilised in the literature search and an example database search are included in 112 
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Appendix 1.  The searches were performed using Cochrane Central Register of Controlled 113 
Trial, Cochrane Database of Systematic Reviews, Embase, Medline. The search was limited 114 
to articles published in the English language after the year 2000. De-duplication was 115 
performed in Endnote and then title and abstract screening was performed manually by a 116 
single author to identify eligible articles. Full text screening was performed by 2 authors. 117 
Eligibility criteria: 118 
Studies were included in the systematic review and meta-analysis if they fulfilled the 119 
following inclusion criteria: 120 
1) Studies investigated the diagnostic accuracy of an abMRI that included the FAST 121 
sequence11.  122 
2) Studies included a comparison with an appropriate reference standard, either the 123 
fpMRI or appropriate follow up/histological analysis. 124 
3) Studies were performed in the screening setting 125 
Screening studies of women at high risk, moderate risk, population risk and at mixed risk of 126 
developing breast cancer were included.  Cross-sectional and cohort studies, including 127 
retrospective cohort studies were included but case control studies and cohorts which were 128 
enriched with a greater proportion of cancer cases were excluded. 129 
Quality assessment 130 
The quality appraisal tools used in this review were selected to be relevant to diagnostic test 131 
studies37,38.  Two authors performed data extraction and quality assessment, initially this was 132 
performed by each author independently and any discrepancies were discussed, and a 133 
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consensus opinion was made in discussion with a third author. Judgements were made on the 134 
level of evidence provided using the Grading of Recommendations Assessment, 135 
Development and Evaluation (GRADE) approach for diagnostic tests and strategies39–42 136 
including the assessment of risk of bias, directness of evidence and of consistency and 137 
precision of results. 138 
Data extraction 139 
Included studies were summarised to detail: number of women, study population, number of 140 
scans, format of the abMRI, reference standard used, sensitivity, specificity, PPV and NPV 141 
for the abMRI and also for the fpMRI if there was sufficient follow up, time to read abMRI 142 
and fpMRI, scan acquisition time, sources of bias. 143 
Meta-analysis 144 
A meta-analysis of accuracy of abMRI was performed for the similar studies. The reference 145 
standard was fpMRI results with histology for fpMRI positives. Forest plots of the 146 
sensitivities and specificities were constructed. To account for the dependency between the 147 
sensitivity and specificity, a bivariate random effect model43 was fitted using the R package 148 
“mada”  for performing meta-analyses of diagnostic accuracy44 to obtain the pooled 149 
sensitivity and specificity estimates and associated 95% confidence intervals (95% CI). The 150 
bivariate random effect model was also used to assess any differences in the sensitivity and 151 
specificity between the studies with only high risk patients and those with population and 152 
moderate risk patients. Similar methodology was used to conduct a meta-analysis comparing 153 






The results of the literature search are illustrated as a PRISMA flowchart in Figure 145. 7 158 
articles (6 studies) met the selection criteria for inclusion in the review11,46–51; One study was 159 
reported in two articles48,49. Table 1 summarises the participant demographic of the 7 articles. 160 
The average age of the participants included in the studies ranged from 44.3 years51 to 54.2 161 
years11.  162 
Table 2 shows the quality assessment results for the 7 included articles. All 7 fulfilled the 163 
inclusion quality criteria for validity and applicability except that none of the studies 164 
validated the tool (abMRI) within the study. However, it could be considered that each study 165 
provided some validity for the others.  Table 3 demonstrates the MRI specifications of the 166 
abMRI scans used in the studies. The table shows variation in the protocols used by the 167 
different studies, including, for example, that results from both 1.5T and 3T scanners were 168 
included in three studies47,50,51, 1.5T alone was used in one study11 and 3T alone in one study 169 
(two articles)48,49 and for one study the strength of magnet was not specified46. 170 
Study population 171 
The included studies varied in study population (Table 1). Three of the studies included 172 
solely women described as being at “high risk” of developing breast cancer46,47,51. These 3 173 
studies described multiple reasons for inclusion of a participant in their study under the 174 
heading of high risk, including BRCA gene mutation, family history, personal past history of 175 
breast cancer and previous atypical histology on biopsy. However, in none of these studies 176 
was the percentage lifetime or ten-year risk defined. Both articles by Chen et al focused on 177 
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women who had dense breasts on mammography but were otherwise at population risk48,49, 178 
although the mechanism for classification of density was not defined in either article. Choi et 179 
al. included women with a personal past history of breast cancer as their study population50, 180 
and the study population in Kuhl’s study was women of mixed risk, above population risk 181 
(mild, moderate and high) including women with family history, women with personal past 182 
history of breast cancer and those with no other risk factor than dense breasts11. 183 
Study design 184 
In one study11 all data was acquired prospectively, while for the other 5 studies46–51 images 185 
from consecutive screening examinations were identified retrospectively and then re-186 
interpreted prospectively. 187 
Reading protocol 188 
AbMRIs and fpMRIs were single reported by radiologists who were expert in breast MRI 189 
interpretation in 5 studies11,46,47,50,51. In contrast, in both articles by Chen et al.48,49 both the 190 
abMRIs and fpMRIs were double reported, the reporting performed independently by two 191 
radiologists, both expert in breast MRI interpretation, with any discordant interpretations 192 
being arbitrated by an experienced third, arbitrating reader. All studies had a paired design, 193 
with each reader examining both abMRI and fpMRI for a series of women.  194 
Chen’s two articles48,49 describe an attempt to reduce recall bias by reporting the abMRI and 195 
fpMRI in two separate sessions, at least one month apart, and randomising the order of the 196 
cases presented to the readers at each session. Four studies11,46,47,51 describe sequential 197 
reading of the two scans for each case with readers interpreting the abMRI first and then 198 
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fpMRI immediately afterwards. In one study only an abMRI, and no fpMRI was acquired50 199 
(reference standard = histology or follow up).  200 
Four articles (3 studies) failed to state whether mammograms were available to readers 201 
during abMRI and fpMRI interpretation46,48,49,51. In 2 studies mammograms were available to 202 
readers reading both abMRI and fpMRI47,50 and in one study they were not available to 203 
readers at all11.  204 
Diagnostic accuracy 205 
Six of 7 articles compared abMRI results with fpMRI (including histology of fpMRI positive 206 
cases) as reference standard. However, 3 of these 6 articles provided no follow up data46,49,51, 207 
one provided single year follow up data for a subset of scans only47 and two provided 2 years 208 
follow up data11,48. In addition, in all 6 articles, histology was performed for fpMRI positive 209 
scans but not for abMRI positive scans (unless there was concordance). A comparative 210 
accuracy assessment of abMRI with fpMRI was therefore not possible. Instead an analysis 211 
was performed of the accuracy of abMRI using fpMRI and histology of fpMRI positives as 212 
reference standard.  213 
One study reported in 2 papers48,49.  Therefore, a total of 3,251 breast MRI scans were 214 
performed in 5 studies11,46,47,49,51, and detected a total of 58 cancers by fpMRI (43/58 invasive 215 
(73.6%))(cancer detection rate = 17.8/1000). All but one of the 58 cancers were detected by 216 
abMRI (57/58 = 98%). It was not specified whether the cancer missed by abMRI was 217 
invasive or not. The diagnostic accuracy data for the 5 studies are summarised in Table 4. 218 
The sensitivity for the abMRI in comparison with the fpMRI (and histology of fpMRI 219 
positive scans) is 100% for all but one study (Chen et al 93.8%)49. Specificity for the abMRI 220 
ranged from 88.3% to 97.0% of that achieved by the fpMRI. 221 
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Only one study50 reported rates for abMRI of early call to abMRI at 6 months (76/799 222 
(9.5%)), recall rate (19/799 (2.4%)) and biopsy rate 17/799 (2%) for a cancer detection rate 223 
by abMRI of 15/1000 women screened (12/799). 224 
Meta-analysis 225 
Meta-analysis was performed of the accuracy of abMRI on the 5 similar studies which used 226 
fpMRI (and histology of fpMRI positives) as reference standard11,46,47,49,51, interpretable as 227 
the abMRI’s exact deficiencies versus fpMRI (Figure 2). The overall sensitivity was 228 
estimated as 94.8% (95% CI 85.5-98.2) and the specificity as 94.6% (95% CI 91.5-96.6) for 229 
the abMRI (Figure 2). The sensitivities did not significantly differ between the studies that 230 
involved high risk patients and those that did not (p=0.98) nor the specificities (p=0.58). 231 
Comparison of abMRI with full protocol (fpMRI) 232 
Three studies had additional follow up (1 or 2 years) 11,47,48 that allowed the comparison of 233 
abMRI with fpMRI; only one of these studies identified any interval cancers 47. Two interval 234 
cancers were missed by both the abMRI and fpMRI 47. The data are summarised in Table 5. 235 
The overall sensitivity over these 3 studies was estimated as 92.1% (95% CI 68.6-98.4) and 236 
the specificity as 93.8% (95% CI 85.4-97.5) for the abMRI compared to an overall sensitivity 237 
of  91.4% (95% CI 68.1-98.1) and specificity of 96.0% (95% CI 93.4-97.7) for the fpMRI 238 
(Figure 3). The sensitivities for abMRI did not significantly differ from those for fpMRI 239 
(p=0.83) nor did the specificities (p=0.37). 240 
Judgements made on level of evidence for studies included in the meta-analysis 241 
The GRADE approach39–42 to quality assessment was applied to the 5 studies that used 242 
fpMRI, with histology for fpMRI positives, as reference standard. Assessment of different 243 
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aspects of the study, including design, risk of bias, indirectness, inconsistency, imprecision 244 
and quality of evidence yielded assessments of evidence quality ranging from High through 245 
Moderate and Low to Very Low (Table 6).  The main sources of bias identified were that the 246 
index tests were not undertaken independently, that readers had knowledge of the index test 247 
when interpreting the reference standard and that only fpMRI positive cases were biopsied so 248 
that the reference standard differed by index test. In addition, there was lack of clarity in the 249 
definition of population studied and imprecision, seen as large confidence intervals 250 
demonstrated for sensitivity. The short or absent follow up of cases presented by studies 251 
further lowered the overall evidence quality. The confidence we can have in the comparative 252 
diagnostic accuracy results, and therefore our overall level of certainty that abMRI and 253 
fpMRI have a similar level of diagnostic accuracy, was assessed as very low. 254 
Time taken to acquire and read the scans 255 
The times taken to acquire and to interpret the abMRI and fpMRI protocols are summarised 256 
in Table 7. For all 3 studies11,46,47 that compared acquisition times of abMRI with fpMRI, the 257 
acquisition time for abMRI (range: 180-264 seconds) was consistently less than that for 258 
fpMRI (1024-1440). For all 3 studies46,47,49 that compared interpretation times of abMRI with 259 
fpMRI, the average interpretation time for the abMRI (range: 42-144 seconds) was 260 
consistently less than that for fpMRI (192-396). 261 
Grade and stage of cancers detected 262 
Four articles included information on grade of cancers detected11,46–48 (Table 8a) and 4 263 
articles included full or partial information on stage of cancers detected11,47,48,50 (Table 8). In 264 
all studies the majority of cancers were invasive (48/68 (71%))(range within studies 58-86%). 265 
Across the studies that reported grade, only a small proportion of invasive cancers were 266 
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Grade 1 (4/34 (12%)), and two thirds of in situ cases detected were high grade DCIS (8/12 267 
(67%)). Across the studies that reported stage or size, the majority of invasive cancers 268 
detected were small, measuring less than or equal to 1cm diameter (26/51 (51%)) and no 269 
invasive cancers measured greater than 2cm diameter. 270 
Comparison of abMRI with mammography 271 
No articles were identified that directly compared abMRI with mammographic modalities 272 
(digital mammography, digital breast tomosynthesis and contrast enhanced spectral 273 
mammography). However, of the studies included in this systematic review, three 274 
studies11,47,49 documented a recent normal screening mammogram as an inclusion criterion 275 
for their participants. Therefore, all cancers identified by abMRI in these three studies were 276 
not identified by mammography. The additional cancer yield (invasive and non-invasive 277 
disease) over mammography achieved by the abMRI in these three articles was stated as 278 
18.15/1000 women screened11, and 13.3/100047, and calculated from the study’s published 279 
figures as 31.4/1000 (15/478)49. However, in none of these articles was the original cancer 280 
detection rate by mammography presented for comparison. 281 
 282 
Discussion 283 
This systematic review has assimilated data from 6 studies, published as 7 articles, which 284 
compare the diagnostic accuracy, for breast cancer detection, of abMRI (protocols that 285 
include the FAST protocol) with acceptable reference standards, most commonly fpMRI, in a 286 
breast cancer screening setting. The original intention of the review had been to present the 287 
comparative accuracy of abMRI versus fpMRI, but to meet that need the ideal study would 288 
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refer for histology if either test recommended it and then follow up for a number of years. No 289 
studies with this ideal design were found, and therefore the results of our meta-analysis are 290 
interpretable as abMRI’s exact deficiencies versus fpMRI and include 5 published studies.  291 
The GRADE approach determined that the overall quality of the current evidence available 292 
about whether abMRI and fpMRI have a similar diagnostic accuracy is very low. Four studies 293 
were published with incomplete or no follow up data46–49,51, one study published one year’s 294 
follow up data50 and one study published two years’ follow up11. Without sufficient follow up 295 
data, levels of absolute sensitivity for both abMRI and fpMRI are likely to be overestimated. 296 
For the smaller numbers of cases that had follow up data reported (within 3 studies that 297 
compared abMRI with fpMRI11,47,48) the risk of bias, inconsistency, imprecision, study design 298 
and flow is otherwise unchanged and the overall assessment of the quality of evidence 299 
remains very low. 300 
Although, in all 7 articles the abMRI interpretation was appropriately blinded to the reference 301 
standard, during 4 studies11,46,47,51, interpretation of the fpMRI (reference standard) was 302 
performed directly after interpretation of the abMRI by the same reader. This study design 303 
includes a risk of bias, since the results of the fpMRI may have been influenced by 304 
knowledge of the abMRI and this could have unpredictable confounding effects. In addition 305 
to there being a mixture of study populations, the included studies either mixed or failed to 306 
specify prevalent or incident screening rounds. Together these factors resulted in a 307 
heterogenous pre-test probability both within and between studies. The small numbers of 308 
participants, and in particular the very small numbers of cancers detected during each study 309 
led to wide confidence intervals, particularly in the assessment of sensitivity, that have 310 
contributed to imprecision. These factors together necessitated the downgrading of the 311 
overall quality of evidence to very low by GRADE criteria. 312 
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Measured times to acquire and to interpret the two protocols were reported by 3 studies11,46,47 313 
and by 3 studies46–49, respectively, and consistently demonstrated shorter times required for 314 
both acquisition and interpretation of abMRI than for fpMRI. The large magnitude of 315 
reduction in time required to acquire and to report the abMRI in comparison with the fpMRI 316 
makes it more likely that these findings are real. 317 
Although no articles were identified that directly compared abMRI, that include the FAST 318 
protocol, with mammographic modalities, indirect evidence from 3 studies suggested that 319 
abMRI is likely to perform better at diagnostic accuracy than mammograms11,47–49. Of note, 320 
one of these studies48,49 included only women assessed as having dense breasts on 321 
mammography for whom we know the sensitivity for cancer detection by mammography is 322 
reduced52. The large magnitude of the apparently superior sensitivity for breast cancer of 323 
abMRI over mammography (demonstrated as additional cancer yield of 13.3/1000 - 324 
31.4/1000) in these 3 studies increases the likelihood that the finding is real and suggests that 325 
abMRI is likely to perform better at diagnostic accuracy of breast cancer detection than 326 
mammography in a screening setting. However, none of these studies investigated the effect 327 
on clinical outcomes of changing screening modality from mammograms to abMRI, and this 328 
review has identified this gap in our current knowledge. 329 
This systematic review was performed as a comprehensive database search to minimise 330 
publication bias, and the review includes articles with a wide geographical distribution. A 331 
weakness of the review is that we took our data from the published articles and did not 332 
attempt to contact the authors of the articles to determine, for example, whether there was any 333 
overlap of data between articles. However, since our assessment of the level of current 334 
evidence is very low, it is unlikely that this assessment would have been altered if we had 335 
discovered further data overlap between any of our included studies.  336 
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Since this systematic review was performed, in November 2019, the results of a study 337 
comparing invasive cancer detection by abMRI directly with digital breast tomosynthesis in 338 
women with dense breasts have been published53. This prospective study, of 1444 339 
comparison scans (abMRI and digital breast tomosynthesis) with randomised order of scan 340 
performance, included the FAST protocol in the abMRI it studied and demonstrated a 341 
significantly higher rate of invasive breast cancer detection for abMRI (11.8/1000 abMRI and 342 
4.8/1000 digital breast tomosynthesis, p = 0.002). These results are broadly in agreement with 343 
and provide some validity for the results of the current systematic review.  344 
Further studies are needed if the diagnostic accuracy comparisons suggested by the existing 345 
evidence are to be validated. However, prior to any policy decisions being made about a 346 
potential change of screening modality to abMRI (either from fpMRI or from mammograms) 347 
the effect on clinical outcomes, cost effectiveness, acceptability and feasibility of any change 348 
will need to be determined within existing screening programmes. Only one study reported 349 
recall rates and biopsy rates for abMRI50 and this leaves a crucial knowledge gap relating to 350 
workforce issues, feasibility and cost. Further research is needed to determine whether 351 
replacing either fpMRI or mammography with abMRI in a screening setting could improve 352 
clinical outcomes (such as achieving a reduction in interval cancer rates) for some women, 353 
and to determine which population of women it could benefit. 354 
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Figure legends 526 
Figure 1: PRISMA flow chart illustrating the results of the literature search 527 
 528 
Figure 2: Forest plot for sensitivity and specificity for abbreviated protocol MRI (for each 529 
study that used full protocol MRI (FP) and histology of FP positives as reference standard) 530 
 531 
Figure 3: Forest plot for sensitivity and specificity for each study with follow-up for 532 
abbreviated protocol (A) and full protocol (B)  533 
 534 
Table legends and footnotes 535 
 536 
Table 1: Demographics and inclusion and exclusion criteria of 7 included full-text articles 537 
Footnotes: *mean, **median, any additional risk over population risk including dense breasts 538 
(23.7%)(defined as classified as 3 or 4 by 4th edition BIRADs criteria), and/or personal history (49.6%) 539 
and/or family history (26.6%), level of risk not specified in article, level of density not specified in 540 
article  541 
 542 
Table 2: Quality assessment for the 7 included full-text articles 543 




1 reference standard read immediately following index test (readers were not blinded to index test 546 
when reading reference standard) 547 
2  reference standard read at least 1 month after index test and the order of the cases presented to 548 
the reader was randomised to minimise recall bias 549 
3 different reference standard applied to index tests that were concordant with reference standard 550 
to those that were discordant (because abMRI positives that were discordant with fpMRI were not 551 
biopsied) 552 
 553 
Table 3: Specifications of abbreviated protocols (AP) and of images available for AP 554 
interpretation 555 
Footnotes: *Time from commencement of contrast injection to acquisition of first post contrast 556 
dynamic scan  557 
 558 
Table 4: Diagnostic accuracy of abbreviated breast MRI (abMRI) with full protocol (fpMRI) 559 
and histology of fpMRI positives as reference standard 560 
 561 
Table 5: Diagnostic accuracy of abbreviated breast MRI (abMRI) with full protocol (fpMRI) for 562 




Table 6: GRADE quality assessment of the level of evidence provided about diagnostic 565 
accuracy of abbreviated breast MRI (abMRI) versus full protocol (fpMRI), with reference 566 
standard biopsy in test positives on either test and follow up to symptomatic cancer 567 
detection 568 
Footnotes: A full quality assessment would include a row for each of the patient-important outcomes 569 
associated with each possible test result (TP, TN, FP, FN and inconclusive results) as well as test 570 
complications and costs. We have presented a simplified summary of the quality and judgement on level 571 
of evidence for the critical outcomes here. 572 
a Judgement on level of evidence provided (High, Moderate, Low or Very Low) was defined along GRADE 573 
guidelines specifically for Diagnostic Test Accuracy studies  and does not imply the level of evidence 574 
required to influence a change in practice, since diagnostic accuracy outcomes are only a surrogate for 575 
patient outcomes 576 
1Relatively short term (1-2 years) or no follow up data was included in the studies enabling only 577 
comparison of abMRI deficiencies versus fpMRI with histology of fpMRI positives 578 
2The terms high risk and dense breasts were not clearly defined (see Table 2) 579 
 580 
Table 7: Time taken to acquire and to interpret abbreviated breast MRI (abMRI) and full 581 
protocol (fpMRI) 582 
 583 
Appendix legends 584 
Appendix 1: An example of literature search conducted, with details 585 
 586 
